EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE III STUDY

被引：0

作者：

Pol, Stanislas ^{[1
,2
]}

Roberts, Stuart K. ^{[3
]}

Andreone, Pietro ^{[4
]}

Younossi, Zobair M. ^{[5
,6
]}

Diago, Moises ^{[7
]}

Lawitz, Eric ^{[8
]}

Focaccia, Roberto ^{[9
]}

Foster, Graham R. ^{[10
]}

Horban, Andrzej ^{[11
]}

Lonjon-Domanec, Isabelle ^{[12
]}

DeMasi, Ralph ^{[13
]}

van Heeswijk, Rolf ^{[14
]}

De Meyer, Sandra ^{[14
]}

Picchio, Gaston ^{[13
]}

Witek, James ^{[13
]}

Zeuzem, Stefan ^{[15
]}

机构：

[1] Univ Paris 05, INSERM, U1016, Paris, France

[2] Cochin Hosp, AP HP, Paris, France

[3] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia

[4] Univ Bologna, Bologna, Italy

[5] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA

[6] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA

[7] Hosp Gen Valencia, Valencia, Spain

[8] Alamo Med Res, San Antonio, TX USA

[9] Emilio Ribas Infect Dis Inst, Sao Paulo, Brazil

[10] Queen Marys Univ London, Inst Cell & Mol Sci, London, England

[11] Med Univ Warsaw, Warsaw, Poland

[12] Janssen Pharmaceut, Paris, France

[13] Tibotec Inc, Titusville, NJ USA

[14] Tibotec BVBA, Beerse, Belgium

[15] Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany

来源：

HEPATOLOGY | 2011年 / 54卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：374A / 375A

页数：2

共 50 条

[1] Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study
Roberts, Stuart
Pol, Stanislas
Andreone, Pietro
Younossi, Zobair
Diago, Moises
Lawitz, Eric J.
Focaccia, Roberto
Foster, Graham R.
Horban, Andrzej
Lonjon-Domanec, Isabelle
Demasi, Ralph
Heeswijk, Rolf V.
Meyer, Sandra D.
Picchio, Gaston
Witek, James
Zeuzem, Stefan
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 177 - 177
[2] IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE III REALIZE STUDY
Roberts, Stuart K.
Andreone, Pietro
Pol, Stanislas
Younossi, Zobair M.
Diago, Moises
Lawitz, Eric
Focaccia, Roberto
Foster, Graham R.
Horban, Andrzej
Lonjon-Domanec, Isabelle
DeMasi, Ralph
van Heeswijk, Rolf
Picchio, Gaston
Witek, James
Zeuzem, Stefan
HEPATOLOGY, 2011, 54 : 1007A - 1008A
[3] Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study
Roberts, Stuart
Younossi, Zobair
Negro, Francesco
Serfaty, Lawrence
Pol, Stanislas
Diago, Moises
Zeuzem, Stefan
Andreone, Pietro
Lawitz, Eric J.
Focaccia, Roberto
Foster, Graham R.
Horban, Andrzej
Lonjon-Domanec, Isabelle
Coate, Bruce
Demasi, Ralph
Picchio, Gaston
Witek, James
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 178 - 179
[4] IMPACT OF INSULIN RESISTANCE ON VIROLOGIC RESPONSE TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: POST-HOC ANALYSIS OF THE REALIZE PHASE III STUDY
Younossi, Zobair M.
Negro, Francesco
Serfaty, Lawrence
Pol, Stanislas
Diago, Moises
Zeuzem, Stefan
Andreone, Pietro
Lawitz, Eric
Roberts, Stuart K.
Focaccia, Roberto
Foster, Graham R.
Horban, Andrzej
Lonjon-Domanec, Isabelle
Coate, Bruce
DeMasi, Ralph
Picchio, Gaston
Witek, James
HEPATOLOGY, 2011, 54 : 1008A - 1009A
[5] PREDICTORS OF VIROLOGIC RESPONSE WITH TELAPREVIR-BASED COMBINATION TREATMENT IN HCV GENOTYPE 1-INFECTED PATIENTS WITH PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: POST-HOC ANALYSIS OF THE PHASE III REALIZE STUDY
Berg, Thomas
Andreone, Pietro
Pol, Stanislas
Roberts, Stuart K.
Younossi, Zobair M.
Diago, Moises
Lawitz, Eric
Focaccia, Roberto
Foster, Graham R.
Horban, Andrzej
Lonjon-Domanec, Isabelle
DeMasi, Ralph
Picchio, Gaston
Witek, James
Zeuzem, Stefan
HEPATOLOGY, 2011, 54 : 375A - 376A
[6] Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results
Mullhaupt, Beat
Zeuzem, Stefan
Andreone, Pietro
Pol, Stanislas
Lawitz, Eric
Diago, Moises
Roberts, S.
Focaccia, Roberto
Younossi, Zobair
Foster, Graham
Horban, Andrzej
Pockros, Paul. J.
Van Heeswijk, Rolf
de Meyer, Sandra
Luo, Donghan
Picchio, Gaston
Beumont, Maria
SWISS MEDICAL WEEKLY, 2011, 141 : 6S - 6S
[7] REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN
Zeuzem, S.
Andreone, P.
Pol, S.
Lawitz, E. J.
Diago, M.
Roberts, S.
Focaccia, R.
Younossi, Z. M.
Foster, G. R.
Horban, A.
Pockros, P. J.
Van Heeswijk, R.
de Meyer, S.
Luo, D.
Picchio, G.
Beumont, M.
JOURNAL OF HEPATOLOGY, 2011, 54 : S3 - S3
[8] Efficacy and safety of telaprevir-based treatment for elderly patients with genotype 1 chronic hepatitis C
Furusyo, N.
Murata, M.
Ogawa, E.
Nomura, H.
Hayashi, J.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 42 : S130 - S130
[9] Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naive Patients: Final Results of Phase 3 ADVANCE Study
Ferenci, Peter
Jacobson, Ira M.
Adda, Nathalie
Bengtsson, Leif
George, Shelley
Kauffman, Robert
Zeuzem, Stefan
SWISS MEDICAL WEEKLY, 2011, 141 : 3S - 3S
[10] TELAPREVIR IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: FINAL RESULTS OF PHASE 3 ADVANCE STUDY
Jacobson, Ira M.
McHutchison, John G.
Dusheiko, Geoffrey M.
Di Bisceglie, Adrian M.
Reddy, Rajender
Bzowej, Natalie H.
Marcellin, Patrick
Muir, Andrew J.
Bengtsson, Leif
Dunne, Ann Marie
Adda, Nathalie
George, Shelley
Kauffman, Robert S.
Zeuzem, Stefan
HEPATOLOGY, 2010, 52 (04) : 427A - 427A

← 1 2 3 4 5 →